CYMBALTA by Eli Lilly and Company is antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the cns. First approved in 2010.
Drug data last refreshed 41m ago · AI intelligence enriched 3h ago
CYMBALTA (duloxetine) is an oral serotonin-norepinephrine reuptake inhibitor (SNRI) approved for depression, anxiety, and central pain conditions. It works by potentiating serotonergic and noradrenergic activity in the central nervous system to produce antidepressant, anxiolytic, and pain-inhibitory effects. Delivered as a delayed-release capsule formulation.
Product is in the LOE-approaching stage with modest Part D spending, indicating a mature asset with declining brand team expansion.
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
The Cymbalta Pregnancy Registry
Cymbalta for Depression as a Complication of Bereavement
Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients
Worked on CYMBALTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CYMBALTA offers career opportunities primarily in mature brand stewardship, payer negotiations, and patient retention strategies rather than growth-phase launches. Professionals joining should expect focus on competitive pricing, generic mitigation, and lifecycle extension rather than market expansion.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo